Current Edition

The Role of Central Laboratories in AD Trials

Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder that mainly affects the elderly population. The prevalence of AD is predicted to increase to 115.4 million by 2050.
Tatiana Souslova at ACM Global Central Lab looks into why despite having the first drug Tacrine, approved by the FDA in 1993, there has been little progress made in the development of pharmacotherapy for AD treatment.…pdf